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Supplementary Methods. 
Gene expression analysis. Related to Fig. 3 and Supplementary Fig. 6. 
Total RNA samples were isolated using the GeneElute kit, following the manufacturer’s protocol 
(Sigma-Aldrich). cDNA synthesis was carried out using the qScript synthesis kit, following the 
manufacturer’s protocol (Quantabio). mRNA expression was measured by quantitative (Q)-PCR 
using SYBR Green Mastermix (Eurogentec Ltd.) and the DNA Engine Opticon 2 system (BioRad). 
Q-PCR primer sequences are outlined in Supplementary information Table 1. 
Mitochondrial copy number. Related to Supplementary Fig. 5. 
Measurement of mitochondrial (mt)DNA copy number has been described by us previously 9. Total 
DNA samples were isolated using the QIAamp DNA Blood Mini Kit, following the manufacturer’s 
protocol (Sigma-Aldrich). Relative copy numbers of the single-copy nuclear-encoded gene beta-2-
microglobulin (B2M) and the mitochondrially encoded gene MTND1 were measured by quantitative 
(Q)-PCR using SYBR Green Mastermix (Eurogentec Ltd.) and the DNA Engine Opticon 2 system 
(BioRad). The Q-PCR primer sequences are in Supplementary Table 1. To determine the mtDNA 
content, relative to nuclear DNA, the following equations were used: 
a. ΔCT = (nucDNA CT − mtDNA CT) 
b. Relative mtDNA content = 2 × 2ΔCT 
a











Supplementary Fig. 1: Genome-wide CRISPR deletion screen in normoxia,
hypoxia, and glucose-free galactose conditions. a, Schematic shows experimental
design of genome-wide CRISPR/Cas9 deletion screen. U2OS-Cas9 cells were
transduced with a lentiviral sgRNA library targeting 18,009 genes (i), and transduced
cells were selected by puromycin for 14-15 days (ii). Cells were then cultured in 25 mM
glucose in either normoxia (normoxia-glucose) or hypoxia (1% O2) (hypoxia-glucose),
or in 25 mM galactose in normoxia (normoxia-galactose) for 5 days (iii), prior to
harvesting and sequencing for sgRNA abundance (iv). Sequencing reads from triplicate
incubations were analysed by the MAGeCK analysis platform. Library versus plasmid
comparisons were performed for each condition, and relative sgRNA abundances were
calculated between experimental conditions. Three independent biological repeat screens
(i-iv) were performed. b, Chart shows total cell counts of the U2OS-Cas9 library cells
cultured for 5 days for each condition from our screen described in (a). n=3; mean±S.D.;
n.s. not significant; *p<0.05. c, Chart shows HRE luciferase activity (RLU) relative to
total cell protein in U2OS-HRE cells cultured in glucose and incubated in normoxia or
hypoxia (1% O2) for 5 days. n=3 technical replicates; mean±S.D; **p<0.01.






















































































































































































































Normoxia-glucose (Library vs Plasmid)














































Supplementary Fig. 2: Genome-wide CRISPR deletion screen in normoxia,
hypoxia, and glucose-free galactose conditions. a-c, Charts show FDR-corrected
significance values of all genes with significantly depleted sgRNAs at different FDR
thresholds in U2OS-Cas9 library cells compared to plasmid control, and cultured under
the indicated conditions from the screen described in Supplementary Fig 1a. Each of the
three biological replicates are shown independently for each condition (normoxia-
glucose; hypoxia-glucose; normoxia-galactose). d-f, Venn diagrams show proportion of
overlapping genes with significantly depleted sgRNAs from each replicate in (a-c). g,
Chart shows overrepresentation analysis of all genes with significantly depleted sgRNAs
from all replicates in (a). h, Chart shows overrepresentation analysis of the common





















Normoxia-glucose (Library vs Plasmid)
Supplementary Fig. 3: CRISPR deletion screen identifies enriched genes in normoxia-
glucose conditions. Chart shows FDR-corrected significance values of all genes with
significantly enriched sgRNAs from U2OS-Cas9 cells transduced with the genome-wide
sgRNA library compared to plasmid control for 5 days in normoxia-glucose conditions.
Selected genes are highlighted in blue. n=3.

















Hypoxia-glucose (Library vs Plasmid)
Supplementary Fig. 4: Hypoxia promotes loss of mitochondrial genes and genes
involved in energy-consuming processes. a, Chart shows overrepresentation analysis of
all genes with significantly depleted sgRNAs from cells incubated in hypoxia-glucose,
transduced with the sgRNA library compared to the plasmid controls. n=3. b, Charts show
relative density of protein bands from western blots in Fig. 2e. Each protein band density
value was normalised to the respective β-Actin (load control) density value. Data




























































































































































































Supplementary Fig. 5: Hypoxia promotes loss of mitochondrial genes and genes involved
in energy-consuming processes. a, Charts show mtDNA copy number calculated by ratio of
MT-ND1 and B2M gene abundance in U2OS and HCT116 cells incubated for 5 days in either
normoxia-glucose or hypoxia-glucose (1% O2). n=3; mean±S.D.; n.s. not significant. b,
Charts show significance values (-log10 p-value) of all significantly depleted genes in
hypoxia-glucose compared to normoxia-glucose at different FDR thresholds (<20%, <30%,
>30%). HIF family genes (left chart), and HIF pathway regulatory genes (right chart) are
highlighted in blue and black respectively. c, Schematic diagram shows interacting genes
from all genes with significantly enriched sgRNAs in hypoxia-glucose compared to
normoxia-glucose from our screen described in Supplementary Fig. 1a. Nodes of genes with
similar functions are boxed, as indicated.


















































































Supplementary Fig. 6: Loss of SDHC improves tumour cell growth in hypoxia. a,
Chart shows SDHC expression in U2OS cells treated with non-targeting control siRNA
(siCtrl), siRNA targeting SDHC (siSDHC) or untreated cells (NT) for 5 days in normoxia-
glucose. n=3; mean±S.D.; n.s. not significant; ***p<0.001. b, Charts show relative %
growth of HCT116, HeLa, and MCF-7 cells cultured for 5 days in normoxia-glucose or
hypoxia-glucose (1% O2), treated with non-targeting control siRNA (siCtrl) or siRNA
targeting SDHC (siSDHC). n=3. mean±S.D.; n.s. not significant; *p<0.05; **p<0.01;
***p<0.001. c, Chart shows oxygen consumption rate (OCR) for U2OS-HRE cells
cultured in 25 mM glucose or galactose, treated serially with oligomycin, FCCP, and
rotenone. Data represented as pmol/min relative to total cellular protein measured
(pmol/min/protein). mean±S.E.M. n=48 technical replicates. d, Chart shows basal and
maximal OCR of cells in (c). Data represented as pmol/min relative to total cellular
protein measured (pmol/min/protein). n=5; mean±S.D.; n.s. not significant; ***p<0.001. e,
Chart shows extracellular acidification rate (ECAR) of cells in (c). Data represented as
mpH/min relative to total cellular protein measured (mpH/min/protein). mean±S.E.M.
n=48 technical replicates.
Supplementary Fig. 7: Galactose sensitises tumour cells to loss of mitochondrial genes, and promotes loss of 








































Supplementary Fig. 7: Galactose sensitises tumour cells to loss of mitochondrial
genes, and promotes loss of genes involved in energy-consuming processes. a-b,
Schematic diagrams show all interacting genes from genes with significantly depleted (a)
or enriched (b) sgRNAs in normoxia-galactose compared to normoxia-glucose. Nodes of
genes with similar functions are boxed, as indicated. c, Schematic diagram shows nodes of
interacting genes with significantly depleted sgRNAs in normoxia-galactose involved in
hexose carbon metabolism. d, Schematic diagram shows truncated Leloir, glycolytic and
pentose phosphate pathways. Pathway genes with significantly enriched sgRNAs in
normoxia-galactose compared to normoxia-glucose are highlighted in brown.
Supplementary Fig. 8: Inhibitory effects of rotenone in normoxia and hypoxia. Chart
shows relative growth of U2OS cells incubated in normoxia or hypoxia (1% O2) in glucose
conditions, either untreated (NT) or treated with 31.25 nM rotenone for 72h. n=3;












Supplementary Fig. 9: Unprocessed western blots and ponceau S-stained membranes.
Related to Fig. 2e and Supplementary Fig. 4b. Densitometry value for hypoxia (Hyp) relative to








Nor Hyp Nor Hyp Nor Hyp Nor Hyp Nor Hyp Nor Hyp
N1 N1N2 N2 N3N3
U2OS HCT116
1.0 1.0 1.0 1.0 1.0 1.0
1.0 1.0 1.0 1.0 1.0 1.0
0.4 0.3 0.3 0.7 0.8 0.7
1.8 0.4 0.5 0.8 0.5 0.6
1.0 1.0 1.0 1.0 1.0 1.00.9 0.6 0.6 0.7 0.8 0.5
1.0 1.0 1.0 1.0 1.0 1.00.8 1.0 0.8 0.9 1.0 0.7














Supplementary Fig. 10: Unprocessed western blots and ponceau S-stained membranes. Related to
Fig. 3c. Densitometry value for hypoxia (Hyp) relative to 1.0 for normoxia (Nor), for each Nor/Hyp






Nor Hyp Nor Hyp Nor Hyp
1.0 1.0 1.00.5 0.5 0.3

















Supplementary Table 1. Selected enriched mitochondrial sgRNAs for hypoxia vs normoxia. 
Related to Fig. 2. Compared to normoxia-glucose, we highlight 31 sgRNAs significantly enriched 
(FDR<30%) in hypoxia that targeted mitochondrial genes. Notably, 9 of these 31 mitochondrial genes 
that had significantly enriched sgRNAs in hypoxia compared to normoxia, were significantly depleted 
(FDR<30%) in normoxia-glucose (*). 
Gene ID Description p-value 
SDHC* succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa 0.033982 
PDSS2 prenyl (decaprenyl) diphosphate synthase, subunit 2 0.230311 
MTERFD2 MTERF domain containing 2 0.230525 
SNAP29* synaptosomal-associated protein, 29kDa 0.280701 
SOD2* superoxide dismutase 2, mitochondrial 0.280701 
POLG polymerase (DNA directed), gamma 0.280701 
MRPL35 mitochondrial ribosomal protein L35 0.280701 
UQCRFS1* ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 0.280701 
NDUFAF2 NADH dehydrogenase (ubiquinone) complex I, assembly factor 2 0.280701 
PET112* PET112 homolog (yeast) 0.280701 
NUBPL nucleotide binding protein-like 0.280701 
GSTK1 glutathione S-transferase kappa 1 0.280701 
DDX28* DEAD (Asp-Glu-Ala-Asp) box polypeptide 28 0.280701 
COA6 cytochrome c oxidase assembly factor 6 homolog (S. cerevisiae) 0.280701 
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa 0.280701 
HSDL2 hydroxysteroid dehydrogenase like 2 0.280701 
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 0.280701 
ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2 0.280701 
COQ7 coenzyme Q7 homolog, ubiquinone (yeast) 0.280701 
OXNAD1 oxidoreductase NAD-binding domain containing 1 0.280701 
REXO2 RNA exonuclease 2 0.280701 
COX20* COX20 cytochrome C oxidase assembly factor 0.280701 
MRPL21* mitochondrial ribosomal protein L21 0.280701 
BDH1 3-hydroxybutyrate dehydrogenase, type 1 0.284931 
POLG2 polymerase (DNA directed), gamma 2, accessory subunit 0.284931 
FDX1L* ferredoxin 1-like 0.284931 
CARS2 cysteinyl-tRNA synthetase 2, mitochondrial 0.284931 
GTPBP10 GTP-binding protein 10 0.284931 
TWNK/C10orf2 chromosome 10 open reading frame 2 0.295728 
CRIF1 growth arrest and DNA-damage-inducible, gamma interacting protein 1 0.295728 
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Supplementary Table 2. QPCR primer sequences. Related to Fig. 3 and Supplementary Fig. 5. 
Gene Forward (5’-3’) Reverse (5’-3’) 
SDHC TCAAACCGTCCTCTGTCTCC AAAGAGAGACCCCTGCACTC 
EGLN3 GATGCTGAAGAAAGGGC CTGGCAAAGAGAGTATCTG 
ACTB CCCAGAGCAAGAGAGG GTCCAGACGCAGGATG 
MTND1 GCCCCAACGTTGTAGGCCCC  AGCTAAGGTCGGGGCGGTGA 
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Supplementary Table 3. siRNA sequences. Related to Fig. 3 and Supplementary Fig. 6. 
 
Gene Sense (5’-3’) Antisense (5’-3’) 
siSDHC AAGAAGAGAUGGAGCGGUU[dT][dT] AACCGCUCCAUCUCUUCUU[dT][dT] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
